Clinical OMICS

MAR-APR 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: http://clinicalomics.epubxp.com/i/798822

Contents of this Issue

Navigation

Page 26 of 47

www.clinicalomics.com March/April 2017 Clinical OMICs 25 Hope Remains While Company Is True The fight against cancer has seen its share of highs and lows over the past several decades, yet there has been an undeniable commonality that has remained consistent—the driving force of innovation . Often set to task on a seemingly simple solution to a minor problem, investigators stumble upon new methodologies that can transform and shape entire fields of research. Because much of the infrastructure for innovation already exists through NGS technology and extensive immunotherapy research, it's not difficult to envi- sion rapid developments over the next several years . "We are developing a roadmap that is aligned to a vision where exome/transcriptome analysis will make its way to clinical standard of care," Dr. Leite stated. "We have great expectations for the NovaSeq platforms to enable exome and transcriptome analysis at higher throughputs and lower costs that will support clinical studies powered with more and more subjects." Yet, sequencing platforms are only one aspect of Illumina's genomic approach to immunotherapy . Dr . Leite told Clinical OMICs that the company is "developing library preparation tools that are on a regulatory path and have the potential to become a standard methodology for tumor assessment in the future. The first market introduction of these tools is with TruSight Tumor 170, which is a tool for tumor profiling, inclusive of the tumor-driving genes and variants that are relevant for therapeutic research and development." Recognizing that NGS is a key technology driver, Hyland said that Thermo Fisher is looking to develop "ampli- con-based panels that work well on low input amounts of DNA or RNA, and can be massively multiplex—with the Oncomine series of assays, built on AmpliSeq technology, being a critical enabler." Hyland continued stating that "the first Oncomine IO assay is the Oncomine Immune Response Research Assay, a single pool that sensitively measures gene expression of approximately 400 genes involved in the immune system, tumor progression, and response." Being a precision medicine company, when Personalis looks toward the future it can't help but stare in the face of the patient within the clinic . "Our feeling is that better immuno-oncology diagnostics and personalized therapeu- tics like neoantigen-based vaccines powered by genomics platforms like ours will help usher in this future," said Dr. Chen . "We, as a society, need smarter methods for identify- ing patients that are likely to respond, and we need ways to boost overall response . We think the future of genomics and immune-oncology are inextricably intertwined." Kind of like chocolate and peanut butter . The number one magazine for translational researchers and healthcare leaders involved in the transfer of omics technologies in clinical diagnostics Exclusive coverage on hot topics including: • Genomic testing and analysis • Applications of omics research • Liquid biopsies/noninvasive diagnostics • Precision medicine • Companion diagnostics • Clinical practice • Big data/informatics researchers and healthcare leaders involved in the transfer of omics technologies in clinical diagnostics transfer of omics technologies in clinical diagnostics Join thousands of dedicated healthcare professionals looking to transform patient care DON'T MISS AN ISSUE Get your FREE subscription: ClinicalOMICs.com/subscription

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAR-APR 2017